Articles of Association for Orphazyme A/S
Mar 25, 2021
Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today held its Annual General Meeting, at which amendments to the Articles of Association of the Company were adopted.
Orphazyme Vedtgter 25. marts 2021
Articles of Association for Orphazyme
Read moreCapital increase of 3,854 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Mar 25, 2021
Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, announces that a share capital increase has been registered with the Danish Business Authority as a result of the exercise of Restricted Share Units by board members. A total of 3,854 shares of nominally DKK 1 each have been issued by the Company at a subscription price per Restricted Share Unit of DKK 61.1895.
Capital increase of 3854 shares in Orphazyme as a result of the exercise of Restricted Share Units
Read moreResolutions passed at the Annual General Meeting
Mar 25, 2021
Orphazyme A/S (ORPHA.CO; ORPH) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today held its Annual General Meeting, at which the Annual General Meeting.
Resolutions passed at the annual general meeting
Read moreOrphazyme announces presentation of 2020 Annual Report
Mar 23, 2021
Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative rare diseases, today announced that the Company will be hosting an investor call during which the Orphazyme management team will be presenting the Company’s 2020 Annual Report. The presentation will be followed by a Q&A session.
Orphazyme announces presentation of 2020 Annual Report
Read moreCorrection: Notice to convene Annual General Meeting
Mar 3, 2021
Orphazyme A/S (ORPHA.CO; ORPH) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the Company’s Annual General Meeting will be held on.
Notice to convene Annual General Meeting
Appendix 1 Candidates for the Board of Directors 2
Appendix 2 Revised Remuneration Policy 1
Read moreNotice to convene Annual General Meeting
Mar 3, 2021
Orphazyme A/S (ORPHA.CO; ORPH) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the Company’s Annual General Meeting will be held on.
Notice to convene Annual General Meeting
Appendix 2 Revised Remuneration Policy 1
Appendix 1 Candidates for the Board of Directors 2
Read moreOrphazyme reports business highlights and financial results in Annual Report 2020
Mar 2, 2021
Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative rare diseases, today reports its business highlights and financial results included in its Annual Report for the period from January 1, 2020 to December 31, 2020.
Orphazyme reports business highlights and financial
Read moreOrphazyme appoints Christophe Bourdon as Chief Executive Officer
Mar 1, 2021
Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced the appointment of Christophe Bourdon as the company’s Chief Executive Officer, effective as of April 1, 2021, following approval from the Board of Directors.
Orphazyme appoints christophe bourdon as chief execu
Read moreOrphazyme announces participation in upcoming virtual investor conferences
Feb 26, 2021
Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative rare diseases, today announced that Anders Vadsholt, interim CEO and CFO of Orphazyme, will be participating in the following upcoming investor conferences.
Orphazyme announces participation in upcoming ...
Read moreCapital increase of 80,553 shares (equivalent to approximately 0.23% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KUMCRI and directed issuance of new shares
Feb 25, 2021
Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today decided on a capital increase as a result of a directed issue of bonus shares to the University of Kansas Medical Center Research Institute, Inc. (“KUMCRI”) and a directed issue of new shares to Kim Stratton, former CEO of the Company. The capital increase was decided pursuant to the Board of Directors’ authorization laid down in Article 3.2 and 3.3 of the Articles of Association.
Capital increase of 80 553 shares
Read more